These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 25499971)

  • 1. Lysophospholipid receptors in drug discovery.
    Kihara Y; Mizuno H; Chun J
    Exp Cell Res; 2015 May; 333(2):171-177. PubMed ID: 25499971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging medicinal roles for lysophospholipid signaling.
    Gardell SE; Dubin AE; Chun J
    Trends Mol Med; 2006 Feb; 12(2):65-75. PubMed ID: 16406843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel implications for lysophospholipids, lysophosphatidic acid and sphingosine 1-phosphate, as drug targets in cancer.
    Peyruchaud O
    Anticancer Agents Med Chem; 2009 May; 9(4):381-91. PubMed ID: 19442039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya).
    Chun J; Brinkmann V
    Discov Med; 2011 Sep; 12(64):213-28. PubMed ID: 21955849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Druggable Lysophospholipid Signaling Pathways.
    Yanagida K; Valentine WJ
    Adv Exp Med Biol; 2020; 1274():137-176. PubMed ID: 32894510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Research progress of the selective sphingosine-1-phosphate receptor 1 agonists].
    Tian YL; Jin J; Wang XJ
    Yao Xue Xue Bao; 2012 Jan; 47(1):7-17. PubMed ID: 22493799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging biology of sphingosine-1-phosphate: its role in pathogenesis and therapy.
    Proia RL; Hla T
    J Clin Invest; 2015 Apr; 125(4):1379-87. PubMed ID: 25831442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insights into the pharmacological relevance of lysophospholipid receptors.
    Mutoh T; Rivera R; Chun J
    Br J Pharmacol; 2012 Feb; 165(4):829-44. PubMed ID: 21838759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacology of the sphingosine-1-phosphate signalling system.
    Zu Heringdorf DM; Ihlefeld K; Pfeilschifter J
    Handb Exp Pharmacol; 2013; (215):239-53. PubMed ID: 23579459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential activation mechanisms of lipid GPCRs by lysophosphatidic acid and sphingosine 1-phosphate.
    Liu S; Paknejad N; Zhu L; Kihara Y; Ray M; Chun J; Liu W; Hite RK; Huang XY
    Nat Commun; 2022 Feb; 13(1):731. PubMed ID: 35136060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Of spiders and crabs: the emergence of lysophospholipids and their metabolic pathways as targets for therapy in cancer.
    Murph M; Tanaka T; Liu S; Mills GB
    Clin Cancer Res; 2006 Nov; 12(22):6598-602. PubMed ID: 17121877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurological S1P signaling as an emerging mechanism of action of oral FTY720 (fingolimod) in multiple sclerosis.
    Lee CW; Choi JW; Chun J
    Arch Pharm Res; 2010 Oct; 33(10):1567-74. PubMed ID: 21052934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effects of sphingosine 1-phosphate on functions of T cell - review].
    Huang WR; Wang LS; DA WM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Aug; 13(4):718-22. PubMed ID: 16129068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell surface receptors in lysophospholipid signaling.
    Anliker B; Chun J
    Semin Cell Dev Biol; 2004 Oct; 15(5):457-65. PubMed ID: 15271291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology.
    Brinkmann V
    Pharmacol Ther; 2007 Jul; 115(1):84-105. PubMed ID: 17561264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fingolimod: Lessons Learned and New Opportunities for Treating Multiple Sclerosis and Other Disorders.
    Chun J; Kihara Y; Jonnalagadda D; Blaho VA
    Annu Rev Pharmacol Toxicol; 2019 Jan; 59():149-170. PubMed ID: 30625282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lysophospholipids and their receptors in the central nervous system.
    Choi JW; Chun J
    Biochim Biophys Acta; 2013 Jan; 1831(1):20-32. PubMed ID: 22884303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Edg family G protein-coupled receptors for lysophospholipids: their signaling properties and biological activities.
    Takuwa Y; Takuwa N; Sugimoto N
    J Biochem; 2002 Jun; 131(6):767-71. PubMed ID: 12038970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological tools for lysophospholipid GPCRs: development of agonists and antagonists for LPA and S1P receptors.
    Im DS
    Acta Pharmacol Sin; 2010 Sep; 31(9):1213-22. PubMed ID: 20729877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Second generation S1P pathway modulators: research strategies and clinical developments.
    Bigaud M; Guerini D; Billich A; Bassilana F; Brinkmann V
    Biochim Biophys Acta; 2014 May; 1841(5):745-58. PubMed ID: 24239768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.